Pak1. Blockade of Pyk2 attenuated BI-induced Gab1, p115 RhoGEF, Rac1, RhoA, and Pak1 activation resulting in reduced SMC migration/proliferation and neointima formation.
T hrombin is generated at the sites of vascular injury because of the exposure of platelets to subendothelial collagen and subsequent activation of the blood clotting process. 1 Thrombin, in addition to its indispensable role in blood clotting, acts as a mitogen and chemotactic factor to a variety of cell types, including fibroblasts and vascular smooth muscle cells (VSMCs). [2] [3] [4] [5] Thrombin mediates its effects via protease-activated receptors 1-4 that are coupled to various G proteins. 2, [5] [6] [7] Many studies have also demonstrated that G protein-coupled receptor (GPCR) agonists, such as angiotensin II, lysophosphatidic acid, and thrombin, transactivate receptor tyrosine kinases in mediating their growth and chemotactic effects. 8, 9 Among the G proteins, Gs, Gi, Gq/11, and G12/13 are coupled to protease-activated receptors 1-4 and mediate thrombin's effects depending on the cell type. [10] [11] [12] Activation of these G proteins via coupling to various phospholipase Cs leads to generation of second messenger molecules, diacylglycerol and inositol 1,4,5-triphosphate, which in turn results in increased intracellular calcium levels and protein kinase C activation. 13 One of the signaling molecules whose activation process depends on calcium is Pyk2.
14 Pyk2 is a proline-rich nonreceptor tyrosine kinase whose function has been linked to cell motility. 15 It was also reported that Pyk2 bridges the GPCR agonist, angiotensin II-mediated calcium-protein kinase C signaling with mitogen-activated protein kinases in VSMCs. 16 Pyk2 has also been shown to be involved in VSMC growth in response to platelet-derived growth factor-BB. 17 However, nothing is known with regards to the role of Pyk2 in thrombininduced human aortic smooth muscle cell (HASMC) growth and migration and injury-induced vascular wall remodeling. Therefore, in the present investigation we sought to address the role of Pyk2 in thrombin-induced HASMC growth and migration. Our findings reveal that thrombin activates Pyk2 in HASMCs and mediates their growth and migration. In addition, activation of Pyk2 is essential for thrombin-induced Grb2-associated binder protein 1 (Gab1)-p115 Rho guanine nucleotide exchange factor (RhoGEF)-Rac1-RhoA-p21-activated kinase 1 (Pak1) stimulation leading to HASMC growth and migration. Furthermore, balloon injury (BI) caused activation of Pyk2, Gab1, p115 RhoGEF, Rac1, RhoA, andimmunoprecipitation, pull-down assays, transfections and transductions, Western blotting, common carotid artery BI, and in vivo smooth muscle cell migration were previously described. [18] [19] [20] [21] [22] [23] All of the experiments involving animals were performed in accordance with the relevant guidelines and regulations approved by the Institutional Animal Care and Use Committee of the University of Tennessee Health Science Center, Memphis, TN. For a detailed description of the methods, please refer to the online-only Data Supplement.
Results
To understand the role of GPCR signaling events in vascular wall remodeling, we have studied the role of Pyk2 in thrombin-induced HASMC growth and migration. Thrombin stimulated Pyk2 tyrosine phosphorylation in a time-dependent manner ( Figure 1A ). Interference with Pyk2 activation by adenovirus-mediated expression of its dominant negative mutant attenuated thrombin-induced HASMC growth and migration ( Figure 1B and 1C) . To explore the signaling events of how Pyk2 mediates HASMC growth and migration, we studied the role of Gab1, a scaffolding adopter protein. 24 Thrombin induced Gab1 tyrosine phosphorylation in a time-dependent manner ( Figure 2A ). Inhibition of Gab1 by its dominant negative mutant blocked thrombin-induced HASMC growth and migration ( Figure 2B and 2C ). In addition, inhibition of Pyk2 activation attenuated thrombin-induced Gab1 tyrosine phosphorylation ( Figure 2D ). To find whether Pyk2-Gab1 signaling leads to activation of any RhoGEFs, we tested the effect of thrombin on the stimulation of p115 RhoGEF, PDZ RhoGEF and leukemia-associated RhoGEF, the RhoA-specific GEFs. 25 Thrombin stimulated the tyrosine phosphorylation of p115 RhoGEF and PDZ RhoGEF but not leukemia-associated RhoGEF in HASMCs ( Figure 3A ). Because p115 RhoGEF activation was found to be robust, we next focused on the role of this RhoGEF in thrombin-induced HASMC growth and migration. siRNA-mediated downregulation of p115 RhoGEF substantially inhibited thrombin-induced HASMC growth and migration ( Figure 3B−3D) . Furthermore, adenovirusmediated expression of either dominant negative Pyk2 or dominant negative Gab1 inhibited thrombin-induced p115 RhoGEF tyrosine phosphorylation ( Figure 3E and 3F) . Because Gab1 is an adaptor molecule, we asked the question whether it directly interacts with p115 RhoGEF. In response to thrombin, p115 RhoGEF was found to be associated with Gab1 in a time-dependent manner ( Figure  3G ). In addition, inhibition of Gab1 activation attenuated thrombin-induced association of p115 RhoGEF with Gab1 ( Figure 3H ). RhoGEFs mediate activation of Rho GTPases by facilitating the exchange of GDP for GTP. 26, 27 To identify the Rho GTPases activated by p115 RhoGEF, first we studied the time course effect of thrombin on Rac1 and RhoA activation. Thrombin stimulated Rac1 and RhoA in a timedependent manner ( Figure 4A ). Interestingly, dominant negative mutant-mediated blockade of either Rac1 or RhoA inhibited thrombin-induced HASMC growth and migration ( Figure 4B and 4C). Downregulation of p115 RhoGEF by its siRNA prevented thrombin-induced Rac1 and RhoA activation ( Figure 4D ). Similarly, inhibition of either Gab1 or Pyk2 by adenovirus-mediated expression of their respective dominant negative mutants also attenuated both Rac1 and RhoA activation ( Figure 4E and 4F) . Previously, we reported that RhoA mediates Rac1 activation downstream to leukemia-associated RhoGEF in response to thrombin in rat aortic smooth muscle cells. 18 So, we asked whether there A, An equal amount of protein from control and the indicated time periods of thrombin (0.5 U/mL) treated HASMCs was analyzed by Western blotting for phosphorylated Pyk2 (pPyk2) using its phosphospecific antibodies and the blot was normalized for the total Pyk2 levels. B and C, HASMCs that were transduced with adenovirus containing green fluorescent protein (Ad-GFP) or adenovirus containing dominant negative Pyk2 (Ad-dnPyk2) and quiesced were subjected to thrombin (0.5 U/mL) induced cell growth (B) or migration (C) assays. Cell growth was measured by [ 3 H]-thymidine incorporation, and MTT assay and cell migration was measured by modified Boyden chamber method. The bar graphs represent mean±SD of 3 independent experiments. *P<0.01 vs control or Ad-GFP; **P<0.01 vs thrombin or Ad-GFP+thrombin.
is any interaction between Rac1 and RhoA in HASMCs in response to thrombin. Inhibition of Rac1 blocked thrombininduced RhoA activation ( Figure 4G ). However, blockade of RhoA stimulation had no effect on Rac1 activation ( Figure  4H ). Because both the Rho GTPases target Pak1, [26] [27] [28] [29] we next wanted to find whether thrombin activates Pak1 in HASMCs. Thrombin induced Pak1 activation in a time-dependent manner ( Figure 5A ). Furthermore, downregulation of Pak1 levels by its siRNA inhibited thrombin-induced HASMC growth and migration ( Figure 5B−5D ). In addition, adenovirusmediated expression of either dominant negative Rac1 or dominant negative RhoA attenuated thrombin-induced Pak1 activation ( Figure 5E and 5F). Downregulation of p115 RhoGEF levels by its siRNA or adenovirus-mediated expression of either dominant negative Gab1 or dominant negative Pyk2 also blocked thrombin-induced Pak1 activation ( Figure  5G −5I). The observed effects with the use of adenoviral vectors for the delivery of dominant negative mutants of the indicated molecules into cells were not because of cell death as transduction with Ad-GFP had little (<5%) effect on HASMC viability ( Figure I in the online-only Data Supplment).
To confirm the role of Pyk2 in thrombin-induced phosphorylation and activation of Gab1, p115 RhoGEF, Rac1, RhoA, and Pak1, we used the siRNA approach. Pyk2 depletion by its siRNA substantially inhibited thrombin-induced Gab1 and p115 RhoGEF tyrosine phosphorylation and Rac1, RhoA, and Pak1 activation ( Figure II in the online-only Data Supplment). Consistent with these observations, siRNA-mediated downregulation of Pyk2 also attenuated thrombin-induced HASMC growth and migration ( Figure III in the online-only Data Supplment). Furthermore, the blockade of Pyk2 activation by its dominant negative mutant had no effect on thrombininduced protein kinase Cδ phosphorylation, suggesting that the role of Pyk2 on Gab1, p115 RhoGEF, Rac1, RhoA, and Pak1 stimulation by thrombin is selective ( Figure IV in the online-only Data Supplement).
To validate these signaling events in vivo, we used BI of rat carotid artery model. BI induced tyrosine phosphorylation of Pyk2, Gab1, and p115 RhoGEF, as well as caused Rac1, RhoA, and Pak1 activation ( Figure 
Discussion
Pyk2 is a calcium-dependent proline-rich tyrosine kinase and plays a role in the regulation of cell migration and proliferation. 14, 15, 30 In addition, it was reported that GPCR agonists, such as angiotensin II, and receptor tyrosine kinase agonists, such as platelet-derived growth factor-BB, activate Pyk2 in VSMCs, mediating the migration and proliferation of these cells. 16, 17 Furthermore, a recent study showed that Pyk2 plays a role in the early inflammatory reactions during atherogenesis. 31 Despite this information, the mechanisms by which Pyk2 influences vascular diseases are not well understood. In this aspect, in the present study, we demonstrate that thrombin activates Pyk2, as well as Gab1, p115 RhoGEF, Rac1, RhoA, and Pak1 in HASMCs ( Figure 6G ). In addition, thrombin-induced activation of Gab1, p115 RhoGEF, Rac1, Thrombin-induced tyrosine phosphorylation of Grb2-associated binder protein 1 (Gab1) requires proline-rich nonreceptor tyrosine kinase 2 (Pyk2) activation. A, An equal amount of protein from control and each time period of thrombin (0.5 U/mL) treated human aortic smooth muscle cells (HASMCs) was immunoprecipitated with anti-Gab1 antibodies and the immunocomplexes were analyzed by Western blotting using anti-PY20 antibodies. The blot was normalized for the total Gab1 levels. B and C, HASMCs that were transduced with adenovirus containing green fluorescent protein (Ad-GFP) or adenovirus containing dominant negative Gab1 (Ad-dnGab1) and quiesced were subjected to thrombin (0.5 U/mL) induced cell growth (B) or migration (C) assays. D, HASMCs that were transduced with Ad-GFP or Ad-dnPyk2 were treated with and without thrombin (0.5 U/mL) for 30 minutes and an equal amount of protein from control and each treatment was immunoprecipitated with antiGab1 antibodies and the immunocomplexes were analyzed by Western blotting using anti-PY20 antibodies. The blot was reprobed sequentially with anti-Pyk2 and anti-Gab1 antibodies to show over expression of dnPyk2 and normalization of Gab1 levels, respectively. The bar graphs represent mean±SD of 3 independent experiments. *P<0.01 vs control or Ad-GFP; **P<0.01 vs thrombin or Ad-GFP+thrombin. pGab1 indicates phosphorylated Gab1. Figure 3 . Proline-rich nonreceptor tyrosine kinase 2 (Pyk2) and Grb2-associated binder protein 1 (Gab1) mediate thrombin activation of rho guanine nucleotide exchange factor (RhoGEF). A, An equal amount of protein from control and each time period of thrombin (0.5 U/mL) treated human aortic smooth muscle cells (HASMCs) was immunoprecipitated with anti-PY20 or anti-p115 RhoGEF antibodies and the immunocomplexes were analyzed by Western blotting using p115 RhoGEF, PDZ RhoGEF, leukemia-associated RhoGEF (LARG), or PY20 antibodies. The blot on the right side was normalized for p115 RhoGEF levels. B, An equal amount of protein from cell extracts of HASMCs that were transfected with control or p115 RhoGEF small interfering RNA (siRNA) was analyzed by Western blotting for p115 RhoGEF and cyclin-dependent kinase 4 (CDK4) levels using their specific antibodies to show the effect of the indicated siRNA on its target and off-target molecules. C and D,HASMCs that were transfected with control or p115 RhoGEF siRNA and quiesced were subjected to thrombin (0.5 U/mL) induced cell growth (B) or migration (C) assays. E and F, An equal amount of protein from HASMCs that were transduced with adenovirus containing green fluorescent protein (Ad-GFP), adenovirus containing dominant negative Pyk2 (Ad-dnPyk2), or adenovirus containing dominant negative Gab1 (Ad-dnGab1), quiesced, and treated with and without thrombin (0.5 U/mL) for 30 minutes was immunoprecipitated with anti-p115 RhoGEF or anti-PY20 antibodies and the immunocomplexes were analyzed by Western blotting using anti-PY20 or anti-p115 RhoGEF antibodies. The blot in E was reprobed sequentially with anti-p115 RhoGEF and anti-Pyk2 antibodies for normalization of p115 RhoGEF levels and to show the overexpression of dnPyk2, respectively. The blot in F was reprobed with anti-Gab1 antibodies to show the overexpression of dnGab1. RhoA, and Pak1 requires Pyk2 stimulation. Furthermore, the present observations clearly show that activation of Pyk2 is required for thrombin-induced HASMC growth and migration. Because both GPCR and receptor tyrosine kinase agonists-induced VSMC growth and migration appear to require Pyk2 activation, it might have a role in VSMC dedifferentiation in response to cues that provoke vessel wall perturbation leading to vascular wall remodeling. Studies from our laboratory, as well as others, have previously reported that Gab1 plays a role in the regulation of VSMC growth/ migration and cardiac hypertrophy. 18, 32, 33 However, there appears to be no information on how Gab1 mediates VSMC migration and proliferation. In this regard, our studies show that Gab1 physically interacts with RhoGEFs, particularly p115 RhoGEF, and facilitates its Pyk2-mediated tyrosine phosphorylation in response to thrombin. A large body of literature suggests that p115 RhoGEF exhibits specificity for RhoA activation. 26, 27 However, our findings indicate that p115 RhoGEF mediates the activation of Rac1, which in turn, leads to RhoA stimulation in response to thrombin. It is interesting to note that in contrast to the antagonism reported between RhoA and Rac1 in the regulation of cell migration, 34 the present observations reveal an interaction between these 2 Rho GTPases in thrombin-induced HASMC growth and migration. Although a similar interaction was observed between these 2 Rho GTPases in the modulation of rat aortic smooth muscle cell migration in response to thrombin, in these cells leukemia-associated RhoGEF-dependent RhoA stimulation is needed for Rac1 activation. 18 Thus, these findings point out clear species differences between human and rat VSMCs in the interaction of Rac1 and RhoA and the mode of their activation by their upstream RhoGEFs in response to thrombin. The Rho GTPase effector Pak1 plays a vital role in cell migration. 28, 29 However, in the present study, we show that Pak1 in addition to its role in cell migration also plays a role in cell proliferation. Recently, it was demonstrated that Gab1 interacts with Pak4 in the regulation of Met receptor-mediated cell migration. 35 It was also reported that Gab1 facilitates Ras-dependent mitogen-activated protein kinases activation in epidermal growth factor-induced epidermal cell proliferation. 36 Based on all of these observations, as well as our previous 18 and present findings, it may be suggested that Gab1 associates with many signaling molecules, including Rho and Ras-specific RhoGEFs, and mediates the activation of their respective downstream signaling events, such as MAPKs, in enhancing the agonistinduced cell migration and proliferation. In this context, we would like to point out that previously we reported a correlation between c-Jun N-terminal kinase 1 activation and VSMC growth in response to thrombin. 37 In addition, many reports showed that small GTPases, Ras, Rac1, Cdc42, and RhoA mediate the activation of c-Jun N-terminal kinase 1 in response to various stimulants. 38, 39 In view of these observations, we may speculate that Pyk2-dependent Gab1-mediated p115 RhoGEF-Rac1/RhoA-Pak1 signaling activation may target c-Jun N-terminal kinase 1 stimulation in facilitating thrombin-induced HASMC growth and migration.
The role of Pyk2 in Gab1 and p115 RhoGEF phosphorylation leading to Rac1-RhoA-Pak1 activation in vitro in HASMCs may be validated in vivo in the carotid artery injury model. BI induced Pyk2 tyrosine phosphorylation very acutely. In addition, we observed that BI activates p115 RhoGEF, Rac1, RhoA, and Pak1 with a time period that correlates with Pyk2 stimulation. The finding that blockade of Pyk2 activation attenuates BI-induced activation of all these molecules suggests that Pyk2 acts upstream to these signaling molecules. Furthermore, inhibition of Pyk2 substantially reduced the presence of SMC on the luminal surface, as . Proline-rich nonreceptor tyrosine kinase 2 (Pyk2) and Grb2-associated binder protein 1 (Gab1) via p115 Rho guanine nucleotide exchange factor (RhoGEF) mediate thrombin-induced Rac1 and RhoA activation. A, An equal amount of protein from control and each time period of thrombin (0.5 U/mL) treated human aortic smooth muscle cell (HASMCs) was subjected to pull-down assay using GST-Pak or GST-Rhotekin conjugated Sepharose CL4B beads and the resultant GST-Pak and GST-Rhotekin-bound proteins were analyzed by Western blotting for Rac1 or RhoA levels using their specific antibodies. An equal amount of protein from the same samples was analyzed by Western blotting for total Rac1 and RhoA levels using their specific antibodies. B and C, After transduction with adenovirus containing green fluorescent protein (Ad-GFP), adenovirus containing dominant negative Rac1 (Ad-dnRac1), or adenovirus containing dominant negative RhoA (Ad-dnRhoA), and quiescence, HASMCs were subjected to thrombin (0.5 U/mL) induced cell growth (B) or migration (C) assays. D, An equal amount of protein from HASMCs that were transfected with control or p115 RhoGEF small interfering RNA (siRNA) and treated with and without thrombin (0.5 U/mL) for 30 minutes were analyzed for Rac1 and RhoA activation as described in A. An equal amount of protein from the same samples was analyzed by Western blotting for total Rac1, RhoA, p115 RhoGEF, and cyclin-dependent kinase 4 levels to show the effect of the indicated siRNA on its target and off-target molecules. E-H, An equal amount of protein from HASMCs that were transduced with Ad-GFP, Ad-dnGab1, Ad-dnPyk2, Ad-dnRac1, or Ad-dnRhoA and treated with and without thrombin (0.5 U/mL) for 30 minutes were analyzed for Rac1 and RhoA activation as described in A. An equal amount of protein from the same samples was analyzed by Western blotting for Rac1, RhoA, Gab1, Pyk2, GFP, and β-tubulin levels to show the overexpression of their respective dominant negative mutants, control vector, or normalization. The bar graphs represent mean±SD of 3 independent experiments. *P<0.01 vs control or Ad-GFP; **P<0.01 vs thrombin or Ad-GFP+thrombin. . Proline-rich nonreceptor tyrosine kinase 2 (Pyk2), Grb2-associated binder protein 1 (Gab1), p115 rho guanine nucleotide exchange factor (RhoGEF), Rac1, and RhoA mediate thrombin-induced Pak1 activation. A, An equal amount of protein from control and each time period of thrombin (0.5 U/mL) treated human aortic smooth muscle cell (HASMCs) was analyzed by Western blotting for pPak1 levels using its specific antibodies and the blot was normalized for total Pak1 levels. B, An equal amount of protein from cell extracts of HASMCs that were transfected with control or Pak1 small interfering RNA (siRNA) was analyzed by Western blotting for Pak1 and β-tubulin levels using their specific antibodies to show the effect of the indicated siRNA on its target and off-target molecules. C and D, HASMCs that were transfected with control or Pak1 siRNA and quiesced were subjected to thrombin (0.5 U/mL) induced cell growth (C) or migration (D) assays. E-I, An equal amount of protein from HASMCs that were transduced with adenovirus containing green fluorescent protein (Ad-GFP), adenovirus containing dominant negative Rac (Ad-dnRac1), adenovirus containing dominant negative RhoA (Ad-dnRhoA), adenovirus containing dominant negative Gab1 (Ad-dnGab1), adenovirus containing dominant negative Pyk2 (Ad-dnPyk2), or transfected with control or p115 RhoGEF siRNA and treated with and without thrombin (0.5 U/mL) for 30 minutes were analyzed by Western blotting for pPak1 levels using its specific antibodies. The blots were reprobed with anti-Rac1, anti-RhoA, anti-p115 RhoGEF, anti-Gab1, anti-Pyk2, anti-GFP, anti-β-tubulin, or anti-cyclin-dependent kinase 4 (CDK4) antibodies to show the overexpression of their respective dominant negative mutants, the siRNA effect on its target molecule level, control vector or for normalization. The bar graphs represent mean±SD of 3 independent experiments. *P<0.01 vs control or Ad-GFP; **P<0.01 vs thrombin or Ad-GFP+thrombin. pPak1 indicates phosphorylated Pak1. Figure 6 . Blockade of proline-rich nonreceptor tyrosine kinase 2 (Pyk2) activation suppresses balloon injury (BI)-induced neointima formation. A-C, Common carotid arteries were dissected out at 12 hours after BI and transduction with adenovirus containing green fluorescent (Ad-GFP) or adenovirus containing dominant negative Pyk2 (Ad-dnPyk2) and tissue extracts were prepared. Tissue extracts containing an equal amount of protein were analyzed by Western blotting for pPyk2 levels using its specific antibodies (A), immunoprecipitated with anti-PY20 antibodies and the immunocomplexes were immunoblotted for Grb2-associated binder protein 1 (Gab1) or p115 rho guanine nucleotide exchange factor levels using their specific antibodies (B) or subjected to pull-down assay for Rac1 and RhoA activation (C). For testing Pak1 activation, tissue extracts were analyzed by Western blotting for pPak1 levels using its phosphospecific antibodies and blot was normalized for total Pak1 and β-tubulin levels (C). The blot in A was reprobed sequentially with anti-Pyk2 and anti-β-tubulin antibodies to show the overexpression of dnPyk2 and normalization, respectively. The bar graphs in A-C represent the mean±SD values of 3 experiments each involving 2-to 4-pooled arteries. D, Three days after BI and transduction with Ad-GFP or AddnPyk2, injured common carotid arteries were dissected out, fixed, opened longitudinally, and stained with anti-smooth muscle cell α (SMCα)-actin antibodies. The SMCα-actin-positive cells were counted and SMC migration was expressed as the number of SMCα-actinpositive cells migrated onto a unit luminal surface area. E, At 1 week post-BI and transduction with Ad-GFP or Ad-dnPyk2, injured common carotid arteries were isolated, fixed, cryosections made and stained for SMCα-actin and Ki67 using their specific antibodies. The SMCα-actin-and Ki67-positive cells were counted to measure neointimal SMC proliferation. F, At 2 weeks post-BI and transduction with Ad-GFP or Ad-dnPyk2, injured common carotid arteries were isolated, fixed, cross sections made, stained with hematoxylin-eosin and the I/M ratios were calculated to measure neointima formation. The bar graphs in D-F represent the quantitative analysis of 6 animals. *P<0.05 vs uninjured; **P<0.05 vs Ad-GFP+BI. 
